Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets

Johnson & Johnson (NYSE:JNJ) is one of the best conservative stocks to buy now. On September 23, the company announced plans to withdraw the LINX Reflux Management System in certain countries.

Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets

Gil C/Shutterstock.com

The company has cited commercial reasons for withdrawing the device used to treat acid reflux disease. The withdrawal follows a thorough evaluation of market conditions and the ability to serve each market effectively. Likewise, the withdrawal is not related to any changes in the safety or efficacy of the device.

The LINX Reflux Management System was approved for patients struggling with chronic gastroesophageal reflux disease. The condition is associated with stomach content leaking backward into the esophagus.

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It offers products for various therapeutic areas, including immunology, such as rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.

While we acknowledge the potential of Johnson & Johnson (NYSE:JNJ) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Performing Penny Stocks to Buy Now and 11 Best Healthcare Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.